EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis

Roberto Furlan iD, Sabine Schaedelin iD, Jette Lautrup Frederiksen iD, Mitsuru Watanabe iD, Noriko Isobe iD, Fredrik Piehl iD, Katharina Fink iD, Ellen Iacobaeus iD, Björn Evertsson iD, Mohsen Khademi iD, Matteo Gastaldi iD, Giacomo Greco iD und 16 weitere

Brain · 2026

DOI: 10.1093/brain/awaf345 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Brain, 2026. Verfasst von Roberto Furlan und 27 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Neuroimmunology Unit, Institute of Experimental Neurology, Division of Neuroscience, IRCCS Ospedale San Raffaele, and Vita e Salute San Raff…. Hauptthemen laut MEDLINE: Neuromyelitis Optica, Multiple Sclerosis, Myelin-Oligodendrocyte Glycoprotein, Granulocytes. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, Health and Labour Sciences Research, Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Granulocytes play a well-established role in the pathogenesis of brain tissue damage in neuromyelitis optica spectrum disorder (NMOSD). The release of granulocyte activation markers (GAM) into CSF has recently been shown to distinguish NMOSD from multiple sclerosis (MS) with high accuracy. However, their pathogenetic role in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is less clear, and their usefulness for diagnostic differentiation is unknown. This observational cohort study by eight tertiary centres in Europe and Japan included 244 CSF samples from patients with MOGAD (n = 71), NMOSD (n = 48), MS (n = 125) and control persons (n = 19). CSF levels of GAM [neutrophil elastase, myeloperoxidase, neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-8 and 9 (MMP-8, MMP-9)], astrocyte damage markers [ADM: glial fibrillary acidic protein (GFAP), S100B], and complement factors C5 and C5a were analysed by capillary ELISA (Ella™) or Luminex®. The primary outcome was the capacity of these markers to differentiate MOGAD, NMOSD and MS in the acute (≤21 days post-exacerbation) stage, and the correlation of GAM with C5 and C5a. Secondary analyses included the correlations of these markers with disability severity, measured by the Expanded Disability Status Scale (EDSS). GAM (except for MMP-9), ADM and C5/C5a levels peaked at onset of disease exacerbation of MOGAD and NMOSD (regardless of aquaporin-4 antibody status), and were significantly higher than in MS. MMP-9 levels were continuously increased in MS over MOGAD and NMOSD, both in acute and subacute/chronic stages. C5 and C5a were equally increased over MS in acute stages of MOGAD and NMOSD. A logistic model and receiver operating characteristics analyses incorporating GAM and C5 displayed high discriminatory power between MOGAD/NMOSD versus MS [area under the curve (AUC) = 0.880], NMOSD versus MS (AUC = 0.837) and MOGAD versus MS (AUC = 0.925) in acute stages. Accordingly, increased ADM levels in NMOSD differentiated NMOSD from MS and MOGAD (AUC = 0.897 and 0.843, respectively). GAM levels correlated with EDSS scores in MOGAD and NMOSD, but not in MS, while those of ADM correlated with disability in NMOSD, but not in MOGAD and MS. Determining CSF levels of GAM and C5/C5a, and of ADM provide a biology-driven approach to differentiate MOGAD, NMOSD and MS. Their measurement can be processed faster and with similar accuracy than with most autoantibody assays, enabling timely initiation of appropriate therapy in acute presentations. The correlation between GAM and C5/C5a levels with neurological impairment in MOGAD and NMOSD corroborates their role as effectors of neural damage, supporting the acute stage use of inhibitors of C5 activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuromyelitis OpticaMultiple SclerosisMyelin-Oligodendrocyte GlycoproteinGranulocytesAstrocytesHumansFemaleMaleAdultMiddle AgedBiomarkersDiagnosis, DifferentialCohort StudiesAutoantibodies

Stichwörter der Autor:innen

CSF biomarkersautoimmunitycomplement activationtranslational research

Substanzen

BiomarkersMyelin-Oligodendrocyte GlycoproteinAutoantibodiesMOG protein, human

Autor:innen und Institutionen

  • Clinical Neuroimmunology Unit, Institute of Experimental Neurology, Division of Neuroscience, IRCCS Ospedale San Raffaele, and Vita e Salute San Raffaele University, Milan 20132, Italy.
  • Department of Clinical Research, University Hospital Basel, University of Basel, Basel 4031, Switzerland.
  • Department of Neurology at Rigshospitalet and Institute of Clinical Medicine, University of Copenhagen, Copenhagen 2100, Denmark.
  • Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
  • Department of Clinical Neuroscience, Karolinska Institutet and Department of Neurology, Karolinska University Hospital, Stockholm SE-171 76, Sweden.
  • Multiple Sclerosis Center, IRCCS Mondino Foundation, and Department of Brain and Behavioural Sciences, University of Pavia, Pavia 27100, Italy.

ORCID-Profile: Roberto Furlan, Sabine Schaedelin, Jette Lautrup Frederiksen, Mitsuru Watanabe, Noriko Isobe, Fredrik Piehl, Katharina Fink, Ellen Iacobaeus, Björn Evertsson, Mohsen Khademi, Matteo Gastaldi, Giacomo Greco, Sara Mariotto, Sara Carta, Johanna Oechtering, Anne-Katrin Pröbstel, Alessandra Mandelli, Daniel C Anthony, Jens Kuhle, David Leppert

Förderung

  • Swiss National Science Foundation
  • Health and Labour Sciences Research
  • Ministry of Health
  • Labour and Welfare of Japan
  • Swedish MRC

Zitieren

APA

Furlan, R., Schaedelin, S., Frederiksen, J. L., Watanabe, M., Isobe, N., Piehl, F., Fink, K., Iacobaeus, E., Evertsson, B., Khademi, M., Gastaldi, M., Greco, G., Mariotto, S., Carta, S., Di Sapio, A., Bava, C. I., Giorgi, L., Benkert, P., Maceski, A. M., …, & Leppert, D. (2026). Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis. Brain. https://doi.org/10.1093/brain/awaf345

Vancouver

Furlan R, Schaedelin S, Frederiksen JL, Watanabe M, Isobe N, Piehl F, et al. Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis. Brain. 2026. doi:10.1093/brain/awaf345

BibTeX
@article{Furlan2026,
  author = {Furlan, Roberto and Schaedelin, Sabine and Frederiksen, Jette Lautrup and Watanabe, Mitsuru and Isobe, Noriko and Piehl, Fredrik and Fink, Katharina and Iacobaeus, Ellen and Evertsson, Björn and Khademi, Mohsen and Gastaldi, Matteo and Greco, Giacomo and Mariotto, Sara and Carta, Sara and Di Sapio, Alessia and Bava, Cecilia Irene and Giorgi, Lucia and Benkert, Pascal and Maceski, Aleksandra Maleska and Oechtering, Johanna and Willemse, Eline and Pröbstel, Anne-Katrin and Pretzsch, Roxanne and Finardi, Annamaria and Mandelli, Alessandra and Anthony, Daniel C and Kuhle, Jens and Leppert, David},
  title = {Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis},
  journal = {Brain},
  year = {2026},
  doi = {10.1093/brain/awaf345}
}
Kostenlos starten →